Clinical trials: cGVHD
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV).
- Trial name
- NCT00436163
- Testing
- Peginterferon alfa-2a
- Where
- 9 sites in Estonia, Latvia and 1 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Chronic Pain
Virtual Pain Care Management (COVID-19)
The COVID-19 pandemic is exacerbating the challenges faced by Veterans at risk of opioid overdose including Veterans prescribed moderate-to-high dose long-term opioid therapy (LTOT) whose usual treatment resources and coping…
- Trial name
- VCPM (NCT04539821)
- Testing
- VCPM
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Chronic Hepatitis B
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability…
- Trial name
- NCT04412863
- Testing
- VIR-2218, pegylated interferon-alfa 2a
- Where
- 22 sites in Australia, Hong Kong and 4 more
- Volunteers
- 84 people
- Sponsor
- Vir Biotechnology, Inc.
Hypertension, Chronic Kidney Disease
Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients
The purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (CKD) patients.
- Trial name
- NCT01284114
- Testing
- Aliskiren
- Where
- 4 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Jichi Medical University
Chronic Low Back Pain
A Study for Patient With Chronic Low Back Pain
The purpose of this study is to determine if duloxetine reduces the severity of chronic low back pain.
- Trial name
- NCT00767806
- Testing
- Duloxetine
- Where
- 26 sites in United States, Brazil and 5 more
- Volunteers
- 401 people
- Sponsor
- Eli Lilly and Company
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GB001 in Adult Participants With Chronic Rhinosinusitis
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients…
- Trial name
- NCT03956862
- Testing
- GB001
- Where
- 38 sites in United States, Czechia and 1 more
- Volunteers
- 97 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Chronic Stable Angina, Refractory Angina
Wave Crossover ECP Study for Simplified Therapy
The purpose of this study is to demonstrate substantial equivalence between Pression's Wave PRO System and a commercially available predicate ECP device to support a U.S. 510(k) submission for the Wave PRO System.
- Trial name
- WaveCRESST (NCT06571370)
- Testing
- External Counterpulsation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Pression
Insomnia Chronic
Prescription Digital Therapeutic for the Treatment of Insomnia
This will be a prospective multi-center controlled trial of 100 patients conducted to assess the real-world effectiveness of a mobile-delivered, prescription digital therapeutic (PDT) device delivering Cognitive Behavioral…
- Trial name
- SLEEP-I (NCT04909229)
- Testing
- PEAR-003b PDT Intervention, Fitbit, Sleep education materials
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Yale University
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Chronic Hepatitis C
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
The purpose of this study is to evaluate the safety and tolerability of AL-335 in combination with odalasvir (ODV) with or without simeprevir (SMV) in participants with genotype (GT)1 or GT2 or GT3 chronic hepatitis C (CHC)…
- Trial name
- NCT02569710
- Testing
- AL-335, Odalasvir (ODV), Simeprevir (SMV)
- Where
- 11 sites in Mauritius, Moldova and 2 more
- Volunteers
- 161 people
- Sponsor
- Alios Biopharma Inc.
Dementia, Chronic Pain
Developing a Pain Identification and Communication Toolkit
The proposed research will develop, refine, and pilot test the Pain Identification and Communication Toolkit (PICT), an intervention to help family caregivers of community-dwelling persons with dementia identify pain symptoms and…
- Trial name
- PICT (NCT03853291)
- Testing
- PICT Workbook, Information Pamphlet
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- SECURE2 (NCT01415518)
- Testing
- Drug: Budesonide/formoterol (Symbicort Turbuhaler, Drug: ipratropium (AtroventTM), theophylline SR
- Where
- 21 sites in China
- Volunteers
- 581 people
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
- Trial name
- NCT00481091
- Testing
- ABT-263
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to see how safe and effective the investigational drug umbralisib (TGR-1202) is in individuals with Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04163718
- Testing
- Umbralisib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q)
WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
This randomized phase II trial studies how well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and…
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome
- Trial name
- NCT02666950
- Testing
- Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Sickle Cell Leg Ulcer
Test of the Safety, Effectiveness, & Acceptability of An Improvised Dressing for Sickle Cell Leg Ulcers in the Tropics
One in 300 Jamaicans have HbSS sickle cell disease, and of these, up to 70% will suffer from sickle cell leg ulcers (SCLUs). Of these, 24% will have a chronic SCLU (one lasting longer than 6 months).
- Trial name
- SCLUJamaica (NCT04479618)
- Testing
- Usual Practice, Improvised dressing, Advanced dressing
- Where
- Jamaica
- Volunteers
- 48 people
- Sponsor
- Benskin, Linda, PhD, RN, SRN (Ghana), CWCN, CWS, DAPWCA
Hepatitis C Virus
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than…
- Trial name
- HEPCAT (NCT01125189)
- Testing
- Daclatasvir, peg-interferon alfa-2a, ribavirin
- Where
- 64 sites in United States, Australia and 9 more
- Volunteers
- 558 people
- Sponsor
- Bristol-Myers Squibb
Chronic Graft-versus-host-disease
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
Extended Treatment and Follow-up of Subjects Treated with Belumosudil in Study KD025-208 or Study KD025-213
- Trial name
- NCT05305989
- Testing
- Belumosudil 200 mg QD, Belumosudil 200 mg BID, Belumosudil 400 mg QD
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Kadmon, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.